Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

8.72 (USD) • At close November 4, 2024
Bedrijfsnaam Arcutis Biotherapeutics, Inc.
Symbool ARQT
Munteenheid USD
Prijs 8.72
Beurswaarde 1,019,289,520
Dividendpercentage 0%
52-weken bereik 1.76 - 13.17
Industrie Biotechnology
Sector Healthcare
CEO Mr. Todd Franklin Watanabe M.A.
Website https://www.arcutis.com

An error occurred while fetching data.

Over Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam

Vergelijkbare Aandelen

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

87.25 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

96.35 USD

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

14.14 USD

Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

LYEL

1.27 USD

BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

BBIO

25.2 USD

Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

56.82 USD

Veru Inc. logo

Veru Inc.

VERU

0.734 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)